Virility Medical is developing intimate skin patch for the treatment of premature ejaculation.
Premature ejaculation is the most common sexual dysfunction. Existing treatments relay mostly on pharmacotherapy. Oral therapies are antidepressant drugs which are usually prescribed off-label. These drugs are with limited efficacy and associated with systemic side effects such as headaches and nausea, as well as sexual side effects such as diminished libido and decreased fertility. Topical therapy is the application of desensitizing creams. This treatment method also offers limited efficacy, along with side effects such as diminished spontaneity and transvaginal absorption resulting in vaginal numbness.
Virility is developing intimate and disposable skin patch. The patch carries an electronic module which generates neuromuscular electrical stimulation. The stimulation is delivered transcutaneously to the adjacent musculature, thus delaying the onset of the premature phase of ejaculation.
Market research shows that the premature ejaculation market is expected to grow at a Compound Annual Growth Rate (CAGR) of 9.6% and reach $2B by 2020. Approximately 20% - 25% of sexually active men suffer from premature ejaculation.
Tal Gollan, B.Sc – CEO & Founder
Tal holds a B.Sc. in Biomedical Engineering from Ben-Gurion University, and has 10 years of experience in the medical device industry.
Dr. Shmuel Springer, Ph.D.
Dr. Springer has a vast experience in the neuromodulation field and served as the former Technology and Clinical Director at Bioness Neuromodulation. Dr. Springer holds a Ph.D. in Physical Therapy from Haifa University.
Dr. Arik Shechter, M.D.
Dr, Shechter currently serves as the Head of Sexual Dysfunction Clinic at the Rambam Medical Center, and holds a M.D. from Ben-Gurion University.